New chemo formula could cut side effects in lymphoma transplants

NCT ID NCT06915246

Recruiting now Disease control Sponsor: VIVUS LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or non-Hodgkin lymphoma. The study aims to see if the ethanol-free version causes fewer infusion-related and other serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carmustine
What this could lead to: If successful, this could offer a safer version of a standard chemotherapy drug used in stem cell transplants for lymphoma, reducing side effects from the ethanol solvent.
What could go wrong: This is an early phase 2 trial with only 49 participants, so results may not apply broadly. The new formulation might not reduce toxicities as hoped, or could have unexpected risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope Atlanta
RECRUITING

Newnan, Georgia, 30265, United States
City of Hope Chicago
RECRUITING

Zion, Illinois, 60099, United States
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
City of Hope Phoenix
RECRUITING

Goodyear, Arizona, 85338, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.